A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs ASLAN 003 (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 29 Jan 2019 According to an ASLAN Pharmaceuticals media release, the company expects to complete the first part of this study in the first half of 2019.
- 09 Jan 2019 Planned number of patients changed from 38 to 56.
- 09 Jan 2019 Planned End Date changed from 1 Dec 2019 to 31 Aug 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History